Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC)

  • STATUS
    Recruiting
  • End date
    Oct 12, 2023
  • participants needed
    1580
  • sponsor
    Alimentiv Inc.
Updated on 4 March 2022
remission
crohn's disease
mesalamine
aminosalicylate

Summary

The purpose of this study is to assess whether withdrawal of aminosalicylate (5-ASA) is non-inferior to continuation of 5-ASA therapy in Crohn's disease (CD) subjects in remission.

Description

Aminosalicylate (5-ASA) agents have proven effective for inducing and maintaining remission in mild to moderate ulcerative colitis (UC) and thus are commonly used as first-line agents for patients with Crohn's disease (CD) in remission. However, there is uncertainty regarding their effectiveness for CD.

In this open-label, randomized study, participants with CD in remission will be allocated to either continue their 5-ASA therapy or withdraw their 5-ASA. The purpose is to investigate if withdrawal of 5-ASA therapy is not unacceptably less effective than continuing on 5-ASA in maintaining CD remission over a 24 month period.

Details
Condition Crohn Disease, Remission
Treatment 5-ASA Withdrawal
Clinical Study IdentifierNCT03261206
SponsorAlimentiv Inc.
Last Modified on4 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Documented diagnosis of CD at least 3 months prior to enrollment
Taking any brand or dosage of an oral aminosalicylate for at least 6 months
Subject-confirmed compliance with current aminosalicylate therapy (taking at least 75% of prescribed doses)
CD currently in clinical remission

Exclusion Criteria

A current diagnosis of UC, indeterminate colitis, microscopic colitis, or diverticular disease-associated colitis
A diagnosis of short-bowel syndrome
Active perianal disease
Active fistulizing disease
A flare of CD within 3 months prior to enrollment requiring initiation/escalation of medical therapy or surgery
Use of systemic corticosteroids for CD (2 continuous weeks or more) within 3 months prior to enrollment
Any major resective bowel surgery for CD (ileal resection, ileocecal resection, proctocolectomy, colectomy, enterectomy, ostomy formation and repair, anastomosis/reanastomosis) within 6 months prior to enrollment
Unwillingness to stop taking aminosalicylates for the duration of the trial
Untreated bile salt malabsorption that, in the opinion of the investigator, may interfere with accurate study HBI assessment
Serious underlying disease other than CD that, in the opinion of the investigator, may interfere with the subject's ability to participate fully in the study
History of active alcohol or drug abuse that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study procedures
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note